{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-021251","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2024-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.344915+00:00","generated_at":"2026-06-05T00:08:28.507105+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cadrenal Therapeutics Q4 2023 update: cash $8.5M, tecarfarin expanded to LVADs and APS","bullets":["Q4 2023 operating expenses (excl. non-cash) totaled $1,160,000; cash used in ops $694,000.","Cash and equivalents at Dec 31, 2023: $8.5 million.","Expanded tecarfarin development to include LVAD and APS patients, addressable market >$2B/yr in US.","Appointed Jeff Cole as COO, overseeing manufacturing, supply chain, IP, and partnering.","Engaged The Sage Group to explore strategic partnerships, co-development, and licensing for tecarfarin."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-021251","json":"https://secwatch.observer/filing/0001213900-24-021251.json","markdown":"https://secwatch.observer/filing/0001213900-24-021251.md","text":"https://secwatch.observer/filing/0001213900-24-021251.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390024021251/0001213900-24-021251-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390024021251/ea0201508-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T00:08:28.507105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f419796d937598f0fe970e321a27b8448f2afeb3","claim":"Cadrenal Therapeutics, Inc. reported financial results for the fiscal year ended December 31, 2023.","evidence_excerpt":"On March 11, 2024, Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for the fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390024021251/0001213900-24-021251-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}